Investing.com - Financial Markets Worldwide

Dae Hwa Pharm Co Ltd (067080)

KOSDAQ
Currency in KRW
14,820
-110(-0.74%)
Closed·

067080 Financial Summary

Key Ratios

P/E Ratio14.14
Price/Book1.9
Debt / Equity62.5%
Return on Equity11.26%
Dividend Yield1.01%
EBITDA11.39B
Fair ValueUnlock
Fair Value UpsideUnlock

Statements Highlights

Period Ending:
2010
31/12
2011
31/12
2012
31/12
2013
31/12
2014
31/12
2015
31/12
2016
31/12
2017
31/12
2018
31/12
2019
31/12
Income Statement
Total Revenues
aa.aaaa.aaaa.aaaa.aaaa.aa139,079.92142,288.25122,199.86110,142.61114,609.57
Gross Profit
aa.aaaa.aaaa.aaaa.aaaa.aa42,008.2744,377.4346,155.8845,099.0348,098.78
Operating Income
aa.aaaa.aaaa.aaaa.aaaa.aa5,590.55,404.138,116.55,130.865,722.92
Net Income
aa.aaaa.aaaa.aaaa.aaaa.aa3,911.013,729.4512,654.476,648.4510,541.13
Balance Sheet
Total Assets
aa.aaaa.aaaa.aaaa.aaaa.aa124,609.12153,803.31165,474.58162,055.38166,145.37
Total Current Liabilities
aa.aaaa.aaaa.aaaa.aaaa.aa47,990.1865,536.468,315.1561,980.9970,680.07
Total Equity
aa.aaaa.aaaa.aaaa.aaaa.aa61,732.373,390.9883,487.9183,199.4884,050.71
Cash Flow
Levered Free Cash Flow
aa.aaaa.aaaa.aaaa.aaaa.aa-3,356.765,620.655,606.72,597.44-3,003.5
Cash from Operations
aa.aaaa.aaaa.aaaa.aaaa.aa2,430.728,788.510,943.0810,489.57-41.07
Cash from Investing
aa.aaaa.aaaa.aaaa.aaaa.aa-3,726.21-25,584.35-14,981.45-7,248.76-3,570.13
Cash from Financing
aa.aaaa.aaaa.aaaa.aaaa.aa107.425,749.11510.75-5,351.5-89.92
Net Change in Cash
aa.aaaa.aaaa.aaaa.aaaa.aa-1,188.098,953.26-3,570.28-1,996.22-3,552.16
* In Millions of KRW (except for per share items)

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 617.61%
Dividend Yield
1.01%
Industry Median 0.93%
Annualised payout
150.00
Paid unevenly
5-Years Growth
-
Growth Streak
Unlock

Earnings

Latest Release
Mar 15, 2023
EPS / Forecast
-130.34 / --
Revenue / Forecast
33.17B / --
EPS Revisions
a
a
Unlock
Last 90 days

FAQ

What were Dae Hwa Pharm's earnings for the latest quarter?

The Dae Hwa Pharm EPS (TTM) is 617.61. Dae Hwa Pharm reported sales of 27,422.80, net income of 866.68, and EPS of -130.34 for the latest quarter.

What was Dae Hwa Pharm's net income for the latest quarter?

Dae Hwa Pharm's net income for the latest quarter was 866.68.

How did Dae Hwa Pharm's performance compare year-over-year in the latest quarter?

The company's revenue moved from 29,370.43 in the previous quarter to 27,422.80 in the latest quarter, and net income moved from 4,010.09 to 866.68 compared to the previous quarter.

What is Dae Hwa Pharm's net profit margin on a TTM basis?

Dae Hwa Pharm's trailing twelve months (TTM) net profit margin is 9.20%.

How does Dae Hwa Pharm's debt to equity ratio compare to industry standards?

Dae Hwa Pharm's total debt-to-equity ratio is 62.50%.

What is Dae Hwa Pharm's return on investment on a TTM basis?

Dae Hwa Pharm's trailing twelve months (TTM) return on investment (ROI) is 11.26%.

Did Dae Hwa Pharm gain or lose cash last quarter?

In the latest quarter, Dae Hwa Pharm's net change in cash was -244.31 million.

What were Dae Hwa Pharm's total assets and liabilities in the latest quarter?

As of the latest quarter, Dae Hwa Pharm reported total assets of 165,605.18 million and total liabilities of 70,551.23 million.

How has Dae Hwa Pharm's total revenue grown this year?

Dae Hwa Pharm's total revenue was 29,370.43 in the previous quarter and 27,422.80 in the latest quarter.

What was Dae Hwa Pharm's revenue per share for the latest quarter?

Dae Hwa Pharm's revenue per share for the latest quarter was 14,478.79.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.